ST. LOUIS, Feb. 10 /PRNewswire-FirstCall/ -- Sigma-Aldrich , a leading Life Science and High Technology company, is pleased to announce the launch of GenomePlex(R) Single Cell Whole Genome Amplification (WGA) Kit.
The new GenomePlex Single Cell WGA Kit supports whole genome amplification from a single cell, resulting in a million-fold amplification yielding microgram quantities of genomic DNA. Providing researchers with a product to amplify genomic DNA from a single cell will help to advance cancer research, genetic profiling and preimplantation genetic diagnostics. The GenomePlex Single Cell WGA Kit will ease the concerns of limited patient source material and provide sufficient DNA for downstream studies. This kit is the latest addition to the GenomePlex Whole Genome Amplification family of products, and includes all of the reagents necessary for cell lysis and whole genome amplification.
"The launch of the new kit greatly expands the research applications of the GenomePlex Whole Genome Amplification technology," said Keith Jolliff, Director of Strategic Marketing in the Research Biotech Business Unit at Sigma-Aldrich. "Not only will this kit advance our understanding of cell biology, but it also has broad applications in the study of various diseases including cancer."
The GenomePlex Single Cell Whole Genome Amplification kit can be used in numerous applications, and is suitable for use with a variety of cells, including fibroblast amniotic cells, renal cancer cells, plant, epithelial, leukemia, and polycarbonate fixed cells. After purification, amplified DNA can be analysed in a manner similar to any genomic or chromosomal DNA sample. A number of downstream applications may be performed, including QPCR, STR analysis, SNP analysis, Comparative Genomic Hybridization (CGH), micro arrays, and other genotyping analysis.
The GenomePlex Single Cell Whole Genome Amplification Kit is derived from the proprietary amplification method that is based upon random fragmentation of the genome into a series of overlapping, short templates. The resulting shorter DNA strands are efficiently primed and amplified to generate a library of DNA fragments with defined 3' and 5' termini, the OmniPlex(R) library. This library is replicated using a linear, isothermal amplification in the initial stages, followed by a limited round of geometric (PCR) amplifications.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 35 countries and has over 6,800 employees providing excellent service worldwide. We are committed to accelerating Customer success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning Web site at http://www.sigma-aldrich.com .
About Rubicon Genomics: Rubicon, located in Ann Arbor, MI, develops and commercializes the OmniPlex(R) family of proprietary amplification technologies for molecular diagnostics and drug development. By combining GenomePlex WGA with related OmniPlex methods to amplify methylated DNA and total RNA, Rubicon has developed an integrated molecular diagnostic test for genetic, epigenetic and expression factors that enables more effective non-invasive early detection and monitoring of cancer and other diseases. Rubicon also provides custom DNA and RNA amplification services to academic and industrial customers. The GenomePlex Whole Genome Amplification technology is licensed by Rubicon Genomics. GenomePlex(R) and OmniPlex are registered trademarks of Rubicon Genomics. More information can be found at http://www.rubicongenomics.com .
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding Company operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
Photo: http://www.newscom.com/cgi-bin/prnh/20050215/CGSIGMAALLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSigma-AldrichCONTACT: Aimee Keithly of Sigma-Aldrich, +1-314-301-2036
